1 / 15

WADA’s Prohibited Substance List: A Psychiatric Perspective

WADA’s Prohibited Substance List: A Psychiatric Perspective. 15 th FINA World Sports Medicine Congress Indianapolis, October 12 th , 2004 Presenter – Saul I Marks, M.D. Toronto, Ontario, Canada. Goals. Consistency in Doping Control is paramount

oihane
Download Presentation

WADA’s Prohibited Substance List: A Psychiatric Perspective

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. WADA’s Prohibited Substance List: A Psychiatric Perspective 15th FINA World Sports Medicine Congress Indianapolis, October 12th, 2004 Presenter – Saul I Marks, M.D. Toronto, Ontario, Canada

  2. Goals • Consistency in Doping Control is paramount • Is there consistency with the “Psychotropic Medications”? • Consistency with Therapeutic Use Exemption • Continuing review of “Psychotropic Medications” is needed

  3. Drug Classification • Psycho-stimulants • The sedative-hypnotics and alcohol • The anti-depressants • Analgesics, anti-psychotics and the mood stabilizers

  4. Attention-Deficit Disorders • Attention-deficit/hyperactivity disorders (ADHD), inattentive type, hyperactive-impulsive type, combined type • 3-5% of children and adolescents • 2-3 times more prevalent in males then females • Most common reason for children to be referred to mental health services DSM - IV

  5. Etiology • Many variable studies • Involvement of both the dopaminergic and catechoaminergic systems • Mesolimbic system involved in hyperactivity, prefrontal cortex involved in symptoms of inattention and impulsivity. Beh and Brain Res, 130 (2002) 65-71

  6. Treatment • First-line treatment are Methylphenidate and Dextroamphetamine • Side effects– sleeplessness, appetite suppression, weight loss and emotional lability • Side effects controlled by decreasing the dose • Prohibited Substance • Therapeutic Use Exemption? Consistency and guidelines Int J Sports Med 2003; 24: 535-540

  7. Guidelines • Proper documentation • History of ADHD and meet criteria for the disorder • Symptom control on stimulant therapy • Documented evidence of response by rating scale • Treatment reviewed regularly, yearly? • Relapse off of treatment

  8. Sedative-Hypnotics and Alcohol • Very few studies, older studies, although alcohol is banned in particular sports and not in others (banned in gymnastics, not in diving) • Limited studies with benzodiazepines and newer agents • Many questions remain regarding performance and these agents with different half-lives, and the newer agents zolpidem and zopiclone • One study showed longer acting benzo caused morning drowsiness and decreased psychomotor performance vs. zopiclone

  9. Further Research? • Could short-acting sedative-hypnotics, and/or newer agents aid sleep night before performance and enhance performance? • Could longer-acting benzodiazepine help performance in low dose or in tolerant person? • Consistency regarding alcohol as a prohibited substance Cl Jour Sport Med, 10; 123-128, 2000

  10. Antidepressant Classes • Monoamine oxidase inhibitors • Tricyclic antidepressants • Selective serotonin reuptake inhibitors • Serotonin-norepinephrine reuptake inhibitor – BUPROPION • Alpha-2 antagonist - mirtazapine • Serotonin antagonist/reuptake inhibitor - nefazadone

  11. Bupropion • Increases levels of both dopamine and norepinephrine, similar to stimulants? • Second-line agent in treatment of ADHD along with Venlofaxine • Does Bupropion warrant further investigation as a potential ergogenic agent? • Consistency

  12. Analgesics, anti-psychotics and the mood stabilizers • Codeine is a permitted substance, morphine is prohibited • Codeine is metabolized to morphine in the liver - ? Consistency? In prohibited substance list? • Anti-psychotics need to be classed alone (tendency to be forgotten as a separate class of drugs?) • Mood Stabilizer – Topiramate – weight loss agent of abuse in the literature, out of competition use?

  13. Summary • TUE in Attention Deficit Disorder • Sedative-Hypnotics and Alcohol deserve further evaluation • Bupropion deserves further evaluation

  14. Questions?

  15. QUESTIONS? • /

More Related